Investor’s Alert: Frontier Communications Corp (NASDAQ:FTR), Unilever N.V. (ADR)(NYSE:UN), AstraZeneca plc (ADR)(NYSE:AZN)

On Thursday, Shares of Frontier Communications Corp (NASDAQ:FTR), subtract -0.50% and closed at $4.00 in the last trading session. The last trading range of the stock ranges between $3.94 and $4.03. Frontier Communications Corporation recently opened its first Frontier Premier retail stores in Southern California, selecting locations in the cities of Norwalk and Pomona for stores that will offer customers a higher level of personal interaction, facilitate local community engagement and enhance Frontier’s business presence in the region.

Featuring interactive demo stations, HD flat-screen TVs and expert staff, the Frontier Premier stores offer consumers a relaxed environment where they can evaluate and purchase various high-tech communications, entertainment products and services Frontier offers for home, office and business. These include quality TV, high-speed internet and phone services. Customers can also check out and learn about Frontier’s business solutions, counting commercial telephone systems. Home phones and tablets will also be available.

“We are excited to open our first Frontier Premier stores in Southern California,” said Cameron Christian, vice president of marketing for Frontier Communications West Region. “Our stores will facilitate us to add a personal touch with a higher level of personal service for our customers and simultaneously strengthen our local engagement presence and deepen our investment in the communities we serve.”

Customers and the community are invited to grand opening celebrations on October 12 for the Norwalk store and October 13 for the Pomona store, with both events running from 10 a.m. to 3 p.m. Following ribbon-cutting ceremonies, guests can enjoy refreshments and giveaways, counting opportunities to win $100 VISA gift cards during three separate drawings at each location.

Unilever N.V. (ADR)(NYSE:UN), dropped -2.72% and closed at $43.56 in the last trading session. The last trading range of the stock ranges between $43.27 and $43.75. The company’s Market capitalization is $130.29 Billion with the total outstanding Shares of 1.28 billion. Unilever N.V. operates in the fast-moving consumer goods market worldwide. The company operates through Personal Care, Foods, Refreshment, and Home Care segments. The Personal Care segment offers skincare and haircare products, deodorants, and oral care products. This segment markets its products under the Dove, Axe, Lux, Rexona, Sunsilk, Lifebuoy, Vaseline, Signal, Zendium, Dermalogica, Murad, Kate Somerville, and REN brand names. The Foods segment provides soups, bouillons, sauces, snacks, mayonnaise, salad dressings, margarines, and spreads under the Knorr, Hellmann’s, Rama, Becel, Maille, Maizena, Fruco, Kissan, Bango, Lady’s Choice, and Becel/Flora brands. The Home Care segment provides home care products, such as powders, liquids and capsules, soap bars, and various cleaning products under the brand names of Omo, Surf, Sunlight, Domestos, Comfort, and Pureit brands. The Refreshment segment offers ice cream and tea-based beverages under the Magnum, Heartbrand (Wall’s), Talenti, Ben & Jerry’s, Cornetto, Grom, Lipton, and PG Tips brand names, in addition to operates T2 stores. The company was formerly known as Margarine Unie N.V. and changed its name to Unilever N.V. in 1929. Unilever N.V. was founded in 1927 and is based in Rotterdam, the Netherlands.

AstraZeneca plc (ADR)(NYSE:AZN), jumped 0.13% and closed at $30.84 in the last trading session. The last trading range of the stock ranges between $30.40 and $30.96. During the 52-week trading session the minimum price at which share price traded, registered at $26.97 and reached to max level of $35.04. AstraZeneca recently declared data from the Phase III FALCON trial demonstrating superior median progression-free survival (PFS) for fulvestrant 500mg contrast to anastrozole 1mg in the 1st line treatment of postmenopausal women with locally-advanced or metastatic breast cancer, who have not had prior hormonal treatment for hormone receptor positive (HR+) breast cancer.1 The primary endpoint was PFS and the FALCON trial enrolled 462 patients.

The results, declared at the 2016 European Society for Medical Oncology (ESMO) Congress, show that the median PFS was 2.8 months longer with fulvestrant than anastrozole (Hazard ratio 0.797; 95% confidence interval: 0.637-0.999; p=0.0486). The median PFS was 16.6 months in the fulvestrant arm, contrast with 13.8 months in the anastrozole arm.1 Aromatase inhibitors, such as anastrozole, are the current standard of care in 1st line treatment for postmenopausal women with hormone-receptor positive (HR+) advanced breast cancer. 2,3,4

Professor Matthew Ellis, Principal Investigator of the FALCON trial, said: “These data document a benefit for fulvestrant in delaying disease progression as a 1st line therapy, an important aim for women with metastatic breast cancer. The results are supported by a previous trial, which also showed an advantage for fulvestrant over anastrozole. The results are clinically meaningful and suggest that fulvestrant could be used as 1st line therapy for women with advanced breast cancer.”

Leave a Reply

Your email address will not be published. Required fields are marked *